Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia

Cathie Wood's ARK ETF significantly rebalanced its portfolio on September 3rd, 2025, notably divesting 53,423 shares of ROKU INC for over $5.12 million, continuing a trend of reducing its position in the streaming company. Concurrently, ARK aggressively increased its exposure to the biotech sector, adding 40,041 shares of CRISPR THERAPEUTICS AG ($2.11M), 53,270 shares of INTELLIA THERAPEUTICS INC ($0.61M), and 105,139 shares of 10X GENOMICS INC ($1.41M). This strategic shift, following recent sales in other consumer tech names, signals ARK's deepening conviction in gene-editing and genomic analysis firms and a broader reallocation towards innovative and disruptive technologies.

Analysis

On September 3rd, 2025, ARK Investment Management executed a significant portfolio rebalancing, signaling a strategic pivot towards the biotechnology sector. The fund divested 53,423 shares of ROKU INC (ROKU) for a total of $5.12 million, extending a recent trend of reducing its position in the streaming company. This divestment suggests a potential revision of ARK's long-term thesis on ROKU. Concurrently, ARK aggressively increased its exposure to gene-editing and genomics, acquiring 40,041 shares of CRISPR THERAPEUTICS (CRSP) for $2.11 million, 105,139 shares of 10X GENOMICS (TXG) for $1.41 million, and 53,270 shares of INTELLIA THERAPEUTICS (NTLA) for $0.61 million. The article highlights that these purchases are part of a consistent accumulation pattern, indicating strong conviction in these names. This capital rotation is contextualized by recent sales of other growth-oriented tech stocks like DRAFTKINGS, COINBASE, and SHOPIFY, reinforcing the narrative of a deliberate reallocation from consumer-facing tech towards foundational, disruptive technologies in the healthcare space.

Key Decisions for Investors

• Investors should recognize ARK's recent trades not as minor rebalancing but as a deliberate capital rotation, signaling a heightened conviction in the long-term prospects of the genomics and gene-editing sectors over certain consumer technology names.
• The continued and significant selling pressure on ROKU from a major growth-focused fund warrants caution; holders of the stock should re-evaluate their thesis in light of this negative institutional signal.
• The consistent accumulation in CRISPR Therapeutics, Intellia Therapeutics, and 10x Genomics by ARK provides a strong bullish signal for these specific companies, suggesting that investors seeking exposure to the biotech space should consider these names for further due diligence.